Evaluation of Japanese encephalitis virus polytope DNA vaccine candidate in BALB/c mice

Virus Research

Volumn 170, Issue 1-2, 2012, Pages 118-125

  Kulkarni, Reshma ^a   Sapkal, Gajanan ^a   Gore, Milind ^a  

^a NATIONAL INSTITUTE OF VIROLOGY   (India)

Author keywords

JEV; Neutralizing antibodies; Polytope; Protection

Indexed keywords

DNA VACCINE; JAPANESE ENCEPHALITIS VACCINE; NEUTRALIZING ANTIBODY; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG EFFICACY; GENE GUN; HUMORAL IMMUNITY; JAPANESE ENCEPHALITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROCONVERSION; VACCINATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; IMMUNIZATION; IMMUNOLOGIC MEMORY; JAPANESE ENCEPHALITIS VACCINES; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; TH1 CELLS; TH2 CELLS; VACCINES, DNA;

JAPANESE ENCEPHALITIS VIRUS; MUS;

EID: 84870553604     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.09.006     Document Type: Article

References (61)

1. Alka, Bharati K., Malik Y.P., Vrati S. Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice. Medical Microbiology and Immunology 2007, 196(4):227-231.
2. Ahsan M.F., Gore M.M. Comparison of immune response generated against Japanese encephalitis virus envelope protein expressed by DNA vaccines under macrophage associated versus ubiquitous expression promoters. Virology Journal 2011, 8(1):382-391.
3. Beasley D.W., Lewthwaite P., Solomon T. Current use and development of vaccines for Japanese encephalitis. Expert Opinion on Biological Therapy 2008, 8:95-106.
4. Belperron A.A., Feltquate D., Fox B.A., Horii T., Bzik D.J. Immune responses induced by gene gun or intramuscular injection of DNA vaccines that express immunogenic region of the serine repeat antigen from Plasmodium falciparum. Infection and Immunity 1999, 67(10):5163-5169.
5. Bharati K., Rani R., Vrati S. Evaluation of Japanese encephalitis virus DNA vaccine candidates in rhesus monkeys [Macaca mulatta]. Vaccine 2009, 27(1):10-16.
6. Biswas, Ayachit S.M., Sapkal V.M., Mahamuni G.N., GoreM.M.S.A. Japanese encephalitis virus produces a CD4+ Th2 response and associated immunoprotection in an adoptive-transfer murine model. Journal of General Virology 2009, 90:818-826.
7. Bourgeois C., Rocha B., Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 2002, 297:2060-2063.
8. Bourgeois C., Veiga-Fernandes H., Joret A.M., Rocha B., Tanchot C. CD8 lethargy in the absence of CD4 help. The European Journal of Immunology 2002, 32(8):2199-2207.
9. Cardoso A.I., Sixt N., Vallier A., Fayolle J., Buckland R., Wild T. Measles virus DNA vaccination: antibody isotype is determined by the method of immunization and by the nature of both the antigen and the coimmunized antigen. Journal of Virology 1998, 72(3):2516-2518.
10. Cecilia D., Gadkari D.A., Kedarnath N., Ghosh S.N. Epitope mapping of Japanese encephalitis virus envelope protein using monoclonal antibodies against an Indian strain. Journal of General Virology 1988, 69(Pt 11):2741-2747.
11. Dewasthaly S.S., Bhonde G.S., Shankarraman V., Biswas S.M., Ayachit V.M., Gore M.M. Chimeric T helper-B cell peptides induce protective response against Japanese encephalitis virus in mice. Protein and Peptide Letters 2007, 14(6):543-551.
12. Doria-Rose N.A., Haigwood N.L. DNA vaccine strategies: candidates for immune modulation and immunization regimens. Methods 2003, 31:207-216.
13. Dormitzer P.R., Galli G., Castellino F., Golding H., Khurana S., Del Giudice G., Rappuoli R. Influenza vaccine immunology. Immunological Reviews 2011, 239(1):167-177.
14. ®]. Drugs 2009, 69:115-122.
15. Dutta K., Nazmi A., Basu A. Chemotherapy in Japanese encephalitis: are we there yet?. Infectious Disorders - Drug Targets 2011, 11(3):300-314.
16. Fei-Fei G., Jian W., Feng X., Li-Ping S., Quan-Yun S., Jin-Ping.Z., Puyan C., Pei-Hong.L. Japanese encephalitis protein vaccine candidates expressing neutralizing epitope and M.T hsp70 induce virus-specific memory B cells and long-lasting antibodies in swine. Vaccine 2008, 26:5590-5594.
17. Feltquate D.M., Heaney S., Webster R.G., Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. The Journal of Immunology 1997, 158(5):2278-2284.
18. Ferguson M., Kurane I., Wimalaratne O., Shin J., Wood D. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June. Vaccine 2007, 25:5233-5243.
19. Gao N., Chen W., Zheng Q., Fan D.Y., Zhang J.L., Chen H., Gao G.F., Zhou D.S., An J. Co-expression of Japanese encephalitis virus prM-E-NS1 antigen with granulocyte-macrophage colony-stimulating factor enhances humoral and anti-virus immunity after DNA vaccination. Immunology Letters 2010, 129(1):23-31.
20. Gangwar R.S., Shil P., Sapkal G.N., Khan S.A., Gore M.M. Induction of virus-specific neutralizing immune response against West Nile and Japanese encephalitis viruses by chimeric peptides representing T-helper and B-cell epitopes. Virus Research 2012, 163(1):40-50.
21. Gore M.M., Gupta A.K., Ayachit V.M., Athawale S.S., Ghosh S.N., Banerjee K. Selection of a neutralization-escape variant strain of Japanese encephalitis virus using monoclonal antibody. Indian Journal of Medical Research 1990, 91:231-233.
22. Guy B., Guirakhoo F., Barban V., Higgs S., Monath T.P., Lang J. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010, 28:632-649.
23. Guzman M.G., Hermida L., Bernardo L., Ramirez R., Guillen G. Domain III of the envelope protein as a dengue vaccine target. Expert Review of Vaccines 2010, 9(2):137-147.
24. Impoinvil, D.E., Baylis, M., Solomon, T. Japanese encephalitis: on the one health agenda. Current Topics in Microbiology and Immunology, in press. http://www.ncbi.nlm.nih.gov/pubmed/22886540.
25. Ishikawa T., Wang G., Widman D.G., Infante E., Winkelmann E.R., Bourne N., Mason P.W. Enhancing the utility of a prM/E-expressing chimeric vaccine for Japanese encephalitis by addition of the JEV NS1 gene. Vaccine 2011, 29(43):7444-7455.
26. Jelinek T. Japanese encephalitis vaccine in travellers. Expert Review of Vaccines 2008, 7:689-693.
27. Jelinek T. Ixiaro: a new vaccine against Japanese encephalitis. Expert Review of Vaccines 2009, 8:1501-1511.
28. Kaur R., Vrati S. Development of a recombinant vaccine against Japanese encephalitis. Journal of Neurovirology 2003, 9(4):421-431.
29. Kollaritsch H., Paulke-Korinek M., Dubischar-Kastner K. IC51 Japanese encephalitis vaccine. Expert Opinion on Biological Therapy 2009, 9:921-931.
30. Kumar P., Sulochana P., Nirmala G., Chandrashekar R., Haridattatreya M., Satchidanandam V. Impaired T Helper 1 function of nonstructural protein 3-specific T cells in Japanese patients with encephalitis with neurological sequelae. The Journal of Infectious Diseases 2004, 189:880-891.
31. H epitopes of Japanese encephalitis virus. Virus Research 2012, 166(1-2):77-86.
32. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nature Reviews Genetics 2008, 9(10):776-788.
33. Larena M., Lobigs M. Immunobiology of Japanese encephalitis virus. Flavivirus Encephalitis 2011, 339-382. InTech Open Access Publisher, Rijeka, Croatia. D. Ruzek (Ed.).
34. Libraty D.H., Nisalak A., Endy T.P., Suntayakorn S., Vaughn D.W., Innis B.L. Clinical and immunological risk factors for severe disease in Japanese encephalitis. Transactions of the Royal Society of Tropical Medicine and Hygiene 2002, 96(2):173-178.
35. Lin C.W., Liu K.T., Huang H.D., Chen W.J. Protective immunity of E. coli-synthesized NS1 protein of Japanese encephalitis virus,. Biotechnology Letters 2008, 30(2):205-214.
36. Lobigs M., Mullbacher A., Wang Y., Pavy M., Lee E. Role of Type 1 and Type 2 interferon responses in recovery from infection with an encephalitic flavivirus. Journal of General Virology 2003, 84(Pt 3):567-572.
37. Lobigs M., Diamond M.S. Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Reviews of Vaccines 2012, 11(2):177-187.
38. Mackenzie J.S., Gubler D.J., Petersen L.R. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nature Medicine 2004, 10(Suppl. 12):S98-S109.
39. Markoff L. Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines. Vaccine 2000, 18(Suppl. 2):26-32.
40. Mukhopadhyay S., Kuhn R.J., Rossmann M.G. A structural perspective of the flavivirus life cycle. Nature Reviews Microbiology 2005, 3(1):13-22.
41. Okamoto S., Yoshii H., Matsuura M., Kojima A., Ishikawa T., Akagi T., Akashi M., Takahashi M., Yamanishi K., Mori Y. Poly-γ-glutamic acid nanoparticles and aluminum adjuvant used as an adjuvant with a single dose of Japanese encephalitis virus-like particles provide effective protection from Japanese encephalitis virus. Clinical and Vaccine Immunology 2012, 19(1):17-22.
42. Oliveira S.C., Rosinha G.M., de-Brito C.F., Fonseca C.T., Afonso R.R., Costa M.C., Goes A.M., Rech E.L., Azevedo V. Immunological properties of gene vaccines delivered by different routes. Brazilian Journal of Medical and Biological Research 1999, 32(2):207-214.
43. Petersen L.R., Roehrig J.T. Flavivirus DNA vaccines - good science, uncertain future. The Journal of Infectious Diseases 2007, 196(12):1721-1723.
44. Pierson T.C., Diamond M.S. Molecular mechanisms of antibody-mediated neutralization of flavivirus infection. Expert Reviews in Molecular Medicine 2008, 12:10-12.
45. Pierson T.C., Fremont D.H., Kuhn R.J., Diamond M.S. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host and Microbe 2008, 4(3):229-238.
46. Saini M., Vrati S. A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virus-neutralizing antibodies and protects mice against lethal challenge. Journal of Virology 2003, 77(6):3487-3494.
47. Samuel M.A., Diamond M.S. α/β interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. Journal of Virology 2005, 79(21):13350-13361.
48. Sapkal G.N., Wairagkar N.S., Ayachit V.M., Bondre V.P., Gore M.M. Detection and isolation of Japanese encephalitis virus from blood clots collected during the acute phase of infection. American Journal of Tropical Medicine and Hygiene 2007, 77(6):1139-1145.
49. Sapkal G.N., Harini S., Ayachit V.M., Fulmali P.V., Mahamuni S.A., Bondre V.P., Gore M.M. Neutralization escape variant of West Nile virus associated with altered peripheral pathogenicity and differential cytokine profile. Virus Research 2011, 158(1-2):130-139.
50. Tafuku S., Miyata T., Tadano M., Mitsumata R., Kawakami H., Harakuni T., Sewaki T., Arakawa T. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice. Microbes and Infection 2012, 14(2):169-176.
51. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007, 370(9602):1847-1853.
52. Tsarev S.A., Sanders M.L., Vaughn D.W., Innis B.L. Phylogenetic analysis suggests only on serotype of Japanese encephalitis virus. Vaccine 2000, 18:36-43.
53. Uchil P.D., Satchidanadam V. Phylogenetic analysis of Japanese encephalitis virus: envelope gene based analysis reveals a fifth genotype, geographic clustering, and multiple introductions of the virus into the Indian subcontinent. American Journal of Tropical Medicine and Hygiene 2001, 65:242-251.
54. Upadhyaya B., Manjunath R. Baker's yeast expressing the Japanese encephalitis virus envelope protein on its cell surface: induction of an antigen-specific but nonneutralizing antibody response. Yeast 2009, 26(7):383-397.
55. van den Hurk A.F., Smit C.S., Field H.E., Smith I.L., Northill J.A., Taylor C.T., Jansen C.C., Smith G.A., Mackenzie J.S. Transmission of Japanese Encephalitis virus from the black flying fox, Pteropusalecto, to Culex annulirostris mosquitoes, despite the absence of detectable viremia. American Journal of Tropical Medicine and Hygiene 2009, 81(3):457-462.
56. Venugopal K., Gould E.A. Towards a new generation of flavivirus vaccines. Vaccine 1994, 12(11):966-975.
57. Verma S.K., Kumar S., Gupta N., Vedi S., Bhattacharya S.M., Lakshmana Rao P.V. Bacterially expressed recombinant envelope protein domain III of Japanese encephalitis virus (rJEV-DIII) elicits Th1 type of immune response in BALB/c mice. Vaccine 2009, 27(49):6905-6909.
58. Wang S., Zhang C., Zhang L., Li J., Huang Z., Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 2008, 26(17):2100-2110.
59. Weiss R., Scheiblhofer S., Freund J., Ferreira F., Livey I., Thalhamer J. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 2002, 20(25-26):3148-3154.
60. Wu Y., Zhang F., Ma W., Song J., Huang Q., Zhang H. A plasmid encoding Japanese encephalitis virus PrM and E proteins elicits protective immunity in suckling mice. Microbiology and Immunology 2004, 48(8):585-590.
61. Zinkernagel R.M. Uncertainties - discrepancies in immunology. Immunological Reviews 2002, 185:103-125.